• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Foresite Capital Management Iv, Llc converted options into 4,041,687 shares and bought $999,990 worth of shares (55,555 units at $18.00) (SEC Form 4)

    2/6/26 7:37:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EIKN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Foresite Capital Management IV, LLC

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Eikon Therapeutics, Inc. [ EIKN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/04/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/04/2026 C(1) 1,340,878 A $0.00 1,340,878 I See Footnote(2)
    Common Stock 02/04/2026 C(1) 335,521 A $0.00 1,676,399 I See Footnote(2)
    Common Stock 02/04/2026 C(1) 37,855 A $0.00 1,714,254 I See Footnote(2)
    Common Stock 02/04/2026 C(1) 229,428 A $0.00 1,943,682 I See Footnote(2)
    Common Stock 02/04/2026 C(1) 697,885 A $0.00 697,885 I See Footnote(3)
    Common Stock 02/04/2026 C(1) 37,855 A $0.00 735,740 I See Footnote(3)
    Common Stock 02/04/2026 C(1) 1,626 A $0.00 737,366 I See Footnote(3)
    Common Stock 02/04/2026 C(1) 67,207 A $0.00 804,573 I See Footnote(3)
    Common Stock 02/04/2026 C(1) 458,855 A $0.00 1,263,428 I See Footnote(3)
    Common Stock 02/04/2026 C(1) 348,942 A $0.00 348,942 I See Footnote(4)
    Common Stock 02/04/2026 C(1) 37,855 A $0.00 386,797 I See Footnote(4)
    Common Stock 02/04/2026 C(1) 922 A $0.00 387,719 I See Footnote(4)
    Common Stock 02/04/2026 C(1) 38,133 A $0.00 425,852 I See Footnote(4)
    Common Stock 02/04/2026 C(1) 408,725 A $0.00 408,725 I See Footnote(5)
    Common Stock 02/04/2026 P 55,555 A $18 1,318,983 I See Footnote(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A Preferred Stock (1) 02/04/2026 C(1) 10,000,000 (1) (1) Common Stock 1,340,878 $0.00 0 I See Footnote(2)
    Series A-1 Preferred Stock (1) 02/04/2026 C(1) 2,502,252 (1) (1) Common Stock 335,521 $0.00 0 I See Footnote(2)
    Series A-1 Preferred Stock (1) 02/04/2026 C(1) 5,204,684 (1) (1) Common Stock 697,885 $0.00 0 I See Footnote(3)
    Series A-1 Preferred Stock (1) 02/04/2026 C(1) 2,602,342 (1) (1) Common Stock 348,942 $0.00 0 I See Footnote(4)
    Series B-1 Preferred Stock (1) 02/04/2026 C(1) 282,317 (1) (1) Common Stock 37,855 $0.00 0 I See Footnote(2)
    Series B-1 Preferred Stock (1) 02/04/2026 C(1) 282,317 (1) (1) Common Stock 37,855 $0.00 0 I See Footnote(3)
    Series B-1 Preferred Stock (1) 02/04/2026 C(1) 282,317 (1) (1) Common Stock 37,855 $0.00 0 I See Footnote(4)
    Series B-1 Preferred Stock (1) 02/04/2026 C(1) 3,048,192 (1) (1) Common Stock 408,725 $0.00 0 I See Footnote(5)
    Series C Preferred Stock (1) 02/04/2026 C(1) 12,123 (1) (1) Common Stock 1,626 $0.00 0 I See Footnote(3)
    Series C Preferred Stock (1) 02/04/2026 C(1) 6,878 (1) (1) Common Stock 922 $0.00 0 I See Footnote(4)
    Series C-1 Preferred Stock (1) 02/04/2026 C(1) 501,219 (1) (1) Common Stock 67,207 $0.00 0 I See Footnote(3)
    Series C-1 Preferred Stock (1) 02/04/2026 C(1) 284,392 (1) (1) Common Stock 38,133 $0.00 0 I See Footnote(4)
    Series D Preferred Stock (1) 02/04/2026 C(1) 1,711,025 (1) (1) Common Stock 229,428 $0.00 0 I See Footnote(2)
    Series D Preferred Stock (1) 02/04/2026 C(1) 3,422,051 (1) (1) Common Stock 458,855 $0.00 0 I See Footnote(3)
    Warrants $43.59 02/14/2025 02/14/2030 Common Stock 17,092 17,092 I See Footnote(2)
    Warrants $43.59 02/14/2025 02/14/2030 Common Stock 34,185 34,185 I See Footnote(3)
    1. Name and Address of Reporting Person*
    Foresite Capital Management IV, LLC

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Foresite Capital Fund IV, L.P.

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Foresite Capital Management V, LLC

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Foresite Capital Fund V, L.P.

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Foresite Capital Opportunity Management V, LLC

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Foresite Capital Opportunity Fund V, L.P.

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Foresite Capital VI-A Management, LLC

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Foresite Capital VI-A, LLC

    (Last) (First) (Middle)
    C/O FORESITE CAPITAL MANAGEMENT
    9200 SUNSET BOULEVARD, SUITE 515

    (Street)
    WEST HOLLYWOOD CA 90069

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.
    2. The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
    3. The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
    4. The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
    5. The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.
    FORESITE CAPITAL MANAGEMENT IV, LLC, By: /s/ James B. Tananbaum, Managing Member 02/06/2026
    FORESITE CAPITAL FUND IV, L.P., By: Foresite Capital Management IV, LLC, Its: General Partner, By: /s/ James B. Tananbaum, Managing Member 02/06/2026
    FORESITE CAPITAL MANAGEMENT V, LLC, By: /s/ James B. Tananbaum, Managing Member 02/06/2026
    FORESITE CAPITAL FUND V, L.P., By: Foresite Capital Management V, LLC, Its: General Partner, By: /s/ James B. Tananbaum, Managing Member 02/06/2026
    FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC, By: /s/ James B. Tananbaum, Managing Member 02/06/2026
    FORESITE CAPITAL OPPORTUNITY FUND V, L.P., By: Foresite Capital Opportunity Management V, LLC, Its: General Partner, By: /s/ James B. Tananbaum, Managing Member 02/06/2026
    FORESITE CAPITAL VI-A MANAGEMENT, LLC, By: /s/ James B. Tananbaum, Managing Member 02/06/2026
    FORESITE CAPITAL VI-A, LLC, By: Foresite Capital VI-A Management, LLC, Its: Managing Member, By: /s/ James B. Tananbaum, Managing Member 02/06/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EIKN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EIKN

    DatePrice TargetRatingAnalyst
    3/2/2026Overweight
    Cantor Fitzgerald
    3/2/2026$32.00Overweight
    Morgan Stanley
    3/2/2026$29.00Overweight
    Analyst
    3/2/2026$26.00Outperform
    Mizuho
    3/2/2026$34.00Buy
    BofA Securities
    2/26/2026$7.00Underperform
    Wedbush
    More analyst ratings

    $EIKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Column Group Iv Gp, Lp converted options into 3,595,340 shares and bought $38,119,680 worth of shares (2,117,760 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/9/26 9:19:00 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Foresite Capital Management Iv, Llc converted options into 4,041,687 shares and bought $999,990 worth of shares (55,555 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/6/26 7:37:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frazier Kenneth C bought $1,999,998 worth of shares (111,111 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/6/26 6:33:01 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/18/26 4:16:58 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13D filed by Eikon Therapeutics Inc.

    SCHEDULE 13D - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/12/26 6:48:54 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/11/26 4:08:44 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Eikon Therapeutics

    Cantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight

    3/2/26 9:11:04 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Eikon Therapeutics with a new price target

    Morgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00

    3/2/26 9:06:14 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on Eikon Therapeutics with a new price target

    Analyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00

    3/2/26 9:05:58 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Klobuchar Michael A

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:04:29 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Huffines Robert Luther

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:02:00 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Frazier Kenneth C

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:01:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care